Health Technology Assessment
- Introduced by
- International HTA organizations, National Institutes of Health
- Year
- 1980
- Type
- Structured assessment methodology
- Family
- Health economics, Evidence-based decision making
What does it do?
Health Technology Assessment (HTA) is a structured, multidisciplinary approach to evaluating the clinical, economic, and societal effects of healthcare technologies (devices, drugs, procedures, systems).
HTA synthesizes evidence from clinical trials, observational studies, and economic analyses to support decision-makers in adoption and reimbursement determinations.
The intuition behind the method
Healthcare organizations and governments face constant demands to fund new technologies (new drugs, surgical robots, diagnostic tests) with competing claims about benefits. HTA provides a framework to answer: Does it work better than existing alternatives? Is the benefit worth the cost? What are the effects on different patient groups and health equity? Rather than relying on manufacturer claims or clinical trial data alone, HTA synthesizes multiple evidence types (efficacy, safety, cost-effectiveness, ethical implications) into a single assessment that informs policy.
History
HTA emerged in the 1970s and 1980s as healthcare costs escalated and pressures grew for evidence-based reimbursement. The US National Institutes of Health Office of Health Technology Assessment pioneered methodology. The International Network of Agencies for Health Technology Assessment (INAHTA), founded in 1993, standardized approaches across countries. Today, HTA is mandatory in many healthcare systems (Australia, Canada, UK, Europe) and is increasingly used by US payers for coverage decisions.
When to use it
Use HTA when evaluating high-cost technologies with significant budget impact, when clinical benefits are uncertain or modest, or when there are multiple competing alternatives. HTA is particularly valuable for medical devices, surgical procedures, diagnostic tests, and new drug formulations seeking reimbursement. Avoid HTA if the technology is well-established, comparator evidence is unavailable, or the decision timeline is too short to complete a rigorous assessment.
Limitations and considerations
- Time-intensive; a complete HTA typically requires 6–12 months or longer
- Quality of recommendations limited by quality of underlying clinical evidence; if trials are small or poorly designed, conclusions are uncertain
- Economic models require assumptions about clinical pathways, treatment discontinuation, and costs; results are sensitive to these assumptions
- Does not directly capture patient preferences and values; separate stakeholder engagement is needed
- Context-specific: recommendations valid in one healthcare system may not apply elsewhere due to differences in costs, practice patterns, and values
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Comprehensive framework integrating clinical, economic, and social evidence into a single recommendation
- Transparent methodology allows stakeholders to understand how conclusions were reached
- Identifies evidence gaps, guiding future research priorities and conditions for coverage
- Applicable globally; can be adapted to different healthcare contexts and values
- Increasingly required by payers, regulatory agencies, and hospital systems for reimbursement decisions
Applications
- Evaluating new cancer drugs for reimbursement by comparing survival benefit and cost-effectiveness to standard chemotherapy
- Assessing surgical technologies (robotic surgery, minimally invasive procedures) on clinical outcomes, cost, and training requirements
- Evaluating diagnostic tests (biomarkers, imaging) on sensitivity/specificity, clinical validity, and cost per correct diagnosis
- Informing hospital procurement decisions for high-cost equipment by comparing performance and total cost of ownership across vendors
- Supporting health policy on coverage of emerging technologies (genetic testing, digital health tools) to ensure equitable access and quality
How it works
How it works
Define the research question precisely: what technology, what patient population, what comparators, what outcomes matter? Conduct a systematic literature review to identify all relevant clinical and economic studies, including unpublished data when possible.
Appraise the quality of identified studies using standardized tools (GRADE for clinical evidence, standard checklists for economic studies). Extract data on clinical outcomes, adverse events, costs, and quality of life impacts.
Synthesize evidence qualitatively and quantitatively. For clinical effects, perform meta-analysis if data permits. For economic effects, calculate cost-effectiveness ratios (cost per quality-adjusted life year gained, QALY).
Develop a decision or economic model integrating clinical and cost data. Use scenarios to test sensitivity to key assumptions. Include analysis of impacts on health equity and vulnerable populations.
Summarize findings in structured HTA report covering clinical effectiveness, cost-effectiveness, organizational implications, and gaps in evidence. Provide recommendations for adoption, further research, or conditional coverage.
Common pitfalls
- Performing HTAs of comparatively simple, low-impact technologies; prioritization is essential to focus limited HTA resources
- Excluding relevant evidence due to language restrictions or poor access to international literature
- Using outdated cost data or failing to adjust for inflation and perspective (patient, provider, societal)
- Basing recommendations on a single meta-analysis or study without considering methodological limitations
- Failing to engage clinicians and patients during assessment; HTA is technical but recommendations must be clinically and socially credible
Frequently asked questions
What is the difference between HTA and economic evaluation?
Economic evaluation (cost-effectiveness analysis, cost-benefit analysis) quantifies the financial impact of a technology. HTA is broader: it integrates economic evaluation with clinical efficacy, safety, ethical, organizational, and social analyses. HTA uses economic evaluation as a component.
How do you quantify the clinical benefit in cost-per-QALY terms?
QALY (Quality-Adjusted Life Year) combines quantity and quality of life: a year in perfect health = 1 QALY, a year with significant disability = 0.5 QALY. A technology that extends life by 2 years but causes side effects resulting in 0.8 QALY per year = 1.6 QALYs gained. Cost per QALY is then total cost divided by QALYs gained.
What is considered a cost-effective threshold?
Different countries set different thresholds. The UK uses £20,000–30,000 per QALY, Australia uses AUD 50,000–65,000. The US typically uses USD 50,000–150,000 per QALY informally. Thresholds reflect values about health priorities and budget constraints; there is no universal standard.
What if there is not enough clinical evidence to perform an HTA?
Recommend conditional coverage: approve the technology under conditions that gather more evidence (e.g., post-market surveillance, mandatory registry entry, or restricted to specialist centers). This allows access while reducing risk of funding ineffective technology.
How do I handle equity issues in HTA?
Analyze subgroup outcomes: does the technology work equally well for different ages, genders, ethnicities, or socioeconomic groups? If benefit varies substantially, report results by subgroup and discuss equity implications. This ensures recommendations do not inadvertently increase health disparities.
Related methods
Sources
Goodman, C. S. (2004). HTA 101: Introduction to Health Technology Assessment (Version 1.0). National Library of Medicine, National Institutes of Health.
Open publication referenceCopied.Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., & Sculpher, M. (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, 346, f1049.
Open DOI referenceCopied.Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford University Press.
Open publication referenceCopied.